Nanotechnology in Ovarian Cancer: Diagnosis and Treatment

Dear Colleagues,

Ovarian cancer is frequently diagnosed at an advanced stage, posing challenges due to limited efficacious treatment options. Nanotechnology presents groundbreaking avenues to enhance early detection, precision drug delivery, and customized therapeutic interventions for individuals affected by ovarian cancer. In the Special Issue titled "Nanotechnology in Ovarian Cancer: Diagnosis and Treatment" in Cancers, we seek to publish cutting-edge research highlighting the latest advancements in the following areas:

Targeted Drug Delivery Approach:

Cutting-edge research focuses on utilizing nanoparticle drug carriers engineered for the precise delivery of chemotherapy drugs to cancer cells. This approach minimizes damage to healthy tissues, enhancing the effectiveness of targeted drug delivery.

Hyperthermia Therapy:

Investigation into the application of magnetic nanoparticles for hyperthermia therapy is a key area of interest. These nanoparticles, when exposed to an external magnetic field, can generate heat selectively, leading to the localized destruction of ovarian cancer cells—an innovative approach to treatment.

Nanoparticle-based Biomarker Detection:

The integration of nanotechnology in the detection of specific biomarkers associated with ovarian cancer is a significant focus. This facilitates the development of personalized diagnostic and treatment strategies tailored to the unique molecular profile of each patient.

Nanoparticle-based Biosensors:

Advancements in the development of nanoscale biosensors are explored for monitoring treatment responses, detecting minimal residual disease, and providing real-time information on ovarian cancer progression. This technology aids in making informed decisions regarding adjustments to treatment plans.

In this Special Issue, we invite contributions that showcase the forefront of research in these areas, shedding light on the potential transformative impact of nanotechnology in the diagnosis and treatment of ovarian cancer.

Dr. Shailendra Kumar Dhar Dwivedi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ovarian cancer
• nanotechnology
• tumor microenvironment
• gynecological malignancies